MARKET OUTLOOK

In the past decade, tumor necrosis factor-alpha (TNF-α) inhibitors, including AbbVie’s Humira and Amgen’s Enbrel, and Janssen’s interleukin IL-12/23 inhibitor Stelara have been leading the U.S. psoriasis biologics market. However, the recent wave of U.S. approvals of novel psoriasis agents is altering the market landscape. Celgene’s oral agent Otezla has been successfully carving out a space in biologics-naive patients. More-effective biologics—the IL-17 inhibitors Novartis’s Cosentyx and Eli Lilly’s Taltz—are threatening the first-line dominance of the TNF-α inhibitors, and Janssen’s IL-23 inhibitor Tremfya is likely to follow. With the recent entry of biosimilars and another IL-23 inhibitor, an IL-17 A/F dual inhibitor, and an oral TYK2 inhibitor in late-phase development, marketers of psoriasis therapies must learn how to overcome the formulary and uptake challenges facing current and emerging therapies in this increasingly competitive market.

QUESTIONS ANSWERED

  • What are the current patient-share leaders among psoriasis biologics/Otezla, and which psoriasis agents do physicians and payers perceive to perform best on specific clinical and market access factors?
  • How do payers cover biosimilar versions of infliximab (Pfizer’s Inflectra, Merck’s Renflexis), and what are physicians’ expected prescribing behaviors toward biosimilars?
  • What are physicians’ perceptions of emerging biologics, such as Skyrizi, mirikizumab, bimekizumab, and BMS-986165, and how do payers anticipate covering these agents?
  • What pharmacoeconomic models and data do payers value given the likely cost and efficacy of novel psoriasis agents?

Table of contents

  • Detailed, Expanded Analysis (US)
    • A&R U.S. Psoriasis

Author(s): Yingdee Unhavaithaya

Yingdee Unhavaithaya is a Business Insights Analyst on the Immune and Inflammatory Disorders team at Decision Resources Group, primarily focusing on psoriasis. Prior to joining DRG, Yingdee was an analyst at Citeline, where he analyzed data on oncology clinical trials ; He was also a business development intern at the Massachusetts General Hospital Research Ventures and Licensing office, where he performed market research to look for invention licensing ; Yingdee received his in cell biology from the University of Massachusetts Medical School, and a in biology from the University of Pittsburgh at Greensburg.


Related Reports

Psoriasis | Current Treatment | Detailed, Expanded Analysis: Treatment Algorithms - Claims Data Analysis - Palmoplantar Pustular Psoriasis/Generalized Pustular Psoriasis (US )

MARKET OUTLOOK Pustular psoriasis is a rare subtype of psoriasis, typically seen as pustules that erupt generally across the body (generalized pustular psoriasis [GPP])...

View Details

Psoriasis | Access and Reimbursement | US | 2018

MARKET OUTLOOK In the past decade, AbbVie’s Humira and Amgen’s Enbrel tumor necrosis factor-alpha (TNF-α) inhibitors and Janssen’s interleukin (

View Details

Psoriasis | Emerging Therapies | Skyrizi Launch Tracking Wave 1 (US)

In the past decade, the TNF-α inhibitors Humira (AbbVie) and Enbrel (Amgen) and the IL-12/23 inhibitor Stelara (J...

View Details

Psoriasis | Landscape & Forecast | Disease Landscape & Forecast

The psoriasis therapy market has become increasingly lucrative owing to the growing use of biologics. The dominance of the tumor necrosis factor (TNF)-a...

View Details